The Desmoid Tumor Research Foundation is dedicated to spreading knowledge about desmoid tumors among clinicians and researchers.
We form partnerships with entities that specialize in creating authorized Continuing Medical Education (CME) credit courses for medical professionals, providing the opportunity and incentive to increase their understanding of this rare tumor type and its treatment.
These courses are available to medical oncologists, surgical oncologists, general surgeons, advanced practice clinicians, and other healthcare professionals involved in the care of patients with desmoid tumors to ensure the greatest potential impact on patient outcomes.
CME-certified programs on desmoid tumors:
Are you equipped with the latest evidence and practical strategies for implementing gamma secretase inhibitors in desmoid tumor care?
Join expert faculty Thierry Alcindor, MD, MSc; Gina Z. D’Amato, MD, FASCO, and Bernd Kasper, MD, PhD, for a symposium developed in collaboration with PeerView Institute for Medical Education.
Activity Description
Through this CME-accredited symposium, you will:
Get current on how contemporary imaging, diagnostic workups, and the latest clinical data and guidelines on gamma secretase inhibitors are reshaping decisions around desmoid tumors.
Learn to tailor personalized desmoid tumor treatments incorporating gamma secretase inhibitors, guided by updated clinical data and guidelines while considering each patient’s disease profile.
Gain practical, multidisciplinary approaches for safely integrating gamma secretase inhibitors into your practice while proactively recognizing and mitigating side effects.
Attend in-person on Wednesday, November 18, at 7:30 PM KST in Seoul during the 2026 CTOS Annual Meeting, or virtually on Thursday, December 3, at 12:00 PM EST.
Past CME-certified programs on desmoid tumors:
Activity Release Date: May 30, 2025
Activity Expiration Date: Expired (content still available without CME credits)
Time to Complete Activity: 30 minutes
Activity Description
Desmoid tumors (DTs) are known for their aggressive and invasive nature, leading to significant morbidity and high recurrence rates. The variability in their presentation and clinical progression often complicates timely and accurate diagnosis, with misdiagnoses frequently causing delays in effective intervention. Historically, complex treatment pathways for DTs have caused uncertainty; however, recent evidence on the gamma-secretase inhibitor, nirogacestat, has shown substantial clinical benefit across patient subgroups, resulting in a remodeled guideline-recommended therapeutic framework for DTs. Is your practice equipped to utilize the latest data to implement patient-centric frameworks for managing these rare and aggressive soft-tissue malignancies?
Join PeerView Live during the 2025 SARC Semiannual Meeting (held before the 2025 ASCO Annual Meeting) to gain a more profound working knowledge for treating DTs in patients with progressive disease. This Seminars & Tumor Board format, in collaboration with The Desmoid Tumor Research Foundation and the Sarcoma Alliance for Research through Collaboration, will showcase expert panelists sharing cutting-edge strategies for implementing personalized frameworks in DTs and clinical applications for GSIs across patient subgroups. Register today to join us for this symposium and get started on improved outcomes for your patients with DTs!
Target Audience
This activity has been designed to meet the educational needs of oncologists, sarcoma specialists, and other clinicians involved in the management of desmoid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize clinical characteristics, diagnostic protocols, current guideline recommendations, and recent safety and efficacy evidence on the use of gamma-secretase inhibitors for the management of desmoid tumors
- Select appropriate systemic treatment options for desmoid tumors that consider current clinical trial evidence, preferred regimens from practice guidelines, and patient-specific factors
- Integrate strategies to address practical aspects of care and improve patient adherence to modern systemic treatment options, including dosing/scheduling considerations, patient education and shared decision-making, care coordination, and adverse event management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty
Co-Chair/Planner
Prof. Patrick Schöffski, MPH
Head, Department of General Medical Oncology
Leuven Cancer Institute
Comprehensive Cancer Center
University Hospitals Leuven
Faculty of Medicine
Department of Oncology
Head, Research Unit Laboratory of Experimental Oncology
KU Leuven
Leuven, Belgium
Co-Chair/Planner
Breelyn A. Wilky, MD
Associate Professor and Director of Sarcoma Medical Oncology University of Colorado Cancer Center
Aurora, Colorado
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, The Desmoid Tumor Research Foundation, and Sarcoma Alliance for Research through Collaboration. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
CME credits expire June 29, 2026
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Copyright © 2000-2025, PeerView
Continue Exploring
Clinicians & Researchers Newsletter
Receive monthly updates about treatment advances, grant applications, clinical trials, CME opportunities, and more.
The Annual DTRF International Desmoid Tumor Research Workshop
DTRF Patient Meeting
Our Annual Patient Meeting is a time to hear from clinicians, researchers, and desmoid patients and caregivers during our annual DTRF Together We Will Weekend.
